This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

DosingMechanism of ActionSafety & TolerabilityEfficacy & Clinical DataSupport & ResourcesMaterialsVideosPrescribing Information
Mechanism of ActionINLYTA® is a selective inhibitor of VEGFR-1, -2 and -31,2Selectivity 

INLYTA® disrupts angiogenesis by selectively targeting VEGF receptors:1,2

  • INLYTA® is a potent small-molecule inhibitor of all known VEGFRs, with lower activity against PDGFR and c-kit3
  • The selectivity of INLYTA® for VEGF receptors could potentially limit off-target toxicity2,3​​​​​​​
VEGF-driven disease Targeting the VEGF pathway is key for combatting advanced RCC1,4-7
  • RCC is a VEGF-driven disease4,5
  • RCC tumours are highly angiogenic and tend to be highly vascular4,8
VEGFR-1, -2 and -3 tyrosine kinase signalling pathways play a pivotal role in pathologic angiogenesis, resulting in tumour growth and metastatic progression of cancer.2,6

VEGFR-1, -2 and -3 tyrosine kinase signalling pathways play a pivotal role in pathologic angiogenesis, resulting in tumour growth and metastatic progression of cancer.2,6 

IC50, half maximal inhibitory concentration. mRCC, metastatic renal cell carcinoma. PDGFR, platelet-derived growth factor receptor. RCC, renal cell carcinoma. TKI, tyrosine kinase inhibitor. VEGF, vascular endothelial growth factor. VEGFR, vascular endothelial growth factor receptor. ReferencesEscudier B & Gore M. Drugs R D 2011;11:113–126.Hu-Lowe DD, et al. Clin Cancer Res 2008;14:7272–7283.Bhargava P & Robinson MO. Curr Oncol Rep 2011;13:103–111.Shen C & Kaelin WG Jr. Semin Cancer Biol 2013;23:18–25.Hakimi AA, et al. Cancer Discov 2019;9:510−525. Hicklin DJ & Ellis LM. J Clin Oncol 2005;23:1011–1027.Ellis LM & Hicklin DJ. Nat Rev Cancer 2008;8:579–591.Aziz SA, et al. J Transl Med 2013;11:15.
Resources Explore Loading

Legal Category: S1A
Further information is available upon request

PP-INL-IRL-0127 December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.